2006 Archive

Accera, Inc., a drug development company focused on Alzheimer's disease and related neurodegenerative diseases, announced it has initiated a multi-center, placebo-controlled Phase IIa study of Ketasyn^TM (AC-1202) for the treatment of Age Associated Memory Impairment (AAMI).

Accera, Inc., a drug development company focused on Alzheimer's disease and related neurodegenerative diseases, announced it has recently closed a Series B financing round of $7.5 million led by Inventages Venture Capital SA. 

Accera announced today the appointment of Lauren C. Costantini, Ph.D., as Vice President of Clinical Development.  She has a distinguished career in neuroscience with experience in all phases of clinical development from research to Phase III clinical trials for therapeutic products ranging from chronic pain and opioid dependency to spinal cord injury and Parkinson's disease.  Most recently she was Director of Product Development at Titan Pharmaceuticals and previously was on the faculty at Harvard Medical School.